Philip J. Mease, MD

Philip J. Mease, MD, is a rheumatologist based in Seattle, Washington and director of the rheumatology research division at Providence Swedish Medical Center.

Articles by Philip J. Mease, MD

Guselkumab's CD64 Binding Offers Targeted IL-23 Inhibition in PsA

ByPhilip J. Mease, MD,Kaitlyn Bader, Assistant Managing Editor

July 10th 2026

Philip J. Mease, MD, reviews guselkumab's mechanism of action and its expanded FDA-approved indication for psoriatic arthritis joint damage inhibition.

APEX Data Reinforce Case For Early PsA Treatment With Guselkumab

ByPhilip J. Mease, MD,Kaitlyn Bader, Assistant Managing Editor

July 8th 2026

Philip J. Mease, MD, explains the rationale for early biologic treatment in psoriatic arthritis following guselkumab's FDA label expansion to address structural joint damage.

Guselkumab APEX Trial Supports New Joint Damage Label

ByPhilip J. Mease, MD,Kaitlyn Bader, Assistant Managing Editor

July 6th 2026

Philip Mease, MD, reviews the APEX trial data supporting guselkumab's expanded FDA label for inhibition of structural joint damage in psoriatic arthritis.

Why Joint Damage Inhibition Matters in Psoriatic Arthritis Treatment

ByPhilip J. Mease, MD,Kaitlyn Bader, Assistant Managing Editor

June 29th 2026

Philip Mease, MD, discusses the FDA's label expansion for guselkumab's inhibition of structural joint damage in psoriatic arthritis.

Study Explores Gaps in Patient-Doctor PsA Priorities

ByMaddi Hebebrand, MC, Associate Editor,Philip J. Mease, MD

January 30th 2025

Researchers found that PsA patients prioritize fatigue, sleep issues, and uncertainty, often ranking them higher than doctors do.

Philip Mease, MD, Discusses Head-to-Head BE BOLD Clinical Trial

ByMaddi Hebebrand, MC, Associate Editor,Philip J. Mease, MD

October 10th 2024

Mease, the lead investigator on the trial, spoke about comparing varying mechanisms of action, primary and secondary endpoints, and how the results of BE BOLD could affect treatment choices.